Current trends and promising clinical utility of IPSC-derived MSC (iMSC)

Shih Hwa Chiou; Han Kiat Alan Ong; Shih Jie Chou; A. F. Aldoghachi; Jit Kai Loh; Nalini Devi Verusingam; Yi Ping Yang; Yueh Chien

doi:10.1016/bs.pmbts.2023.04.002

Current trends and promising clinical utility of IPSC-derived MSC (iMSC)

Shih Hwa Chiou, Han Kiat Alan Ong, Shih Jie Chou, A. F. Aldoghachi, Jit Kai Loh, Nalini Devi Verusingam, Yi Ping Yang^*, Yueh Chien

^*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

2 Scopus citations

Abstract

Mesenchymal stem cells (MSCs) differentiated from human induced pluripotent stem cells (iPSC) or induced MSC (iMSCs) are expected to address issues of scalability and safety as well as the difficulty in producing homogenous clinical grade MSCs as demonstrated by the promising outcomes from preclinical and clinical trials, currently ongoing. The assessment of iMSCs based in vitro and in vivo studies have thus far showed more superior performance as compared to that of the primary or native human MSCs, in terms of cell proliferation, expansion capacity, immunomodulation properties as well as the influence of paracrine signaling and exosomal influence in cell-cell interaction. In this chapter, an overview of current well-established methods in generating a sustainable source of iMSCs involving well defined culture media is discussed followed by the properties of iMSC as compared to that of MSC and its promising prospects for continuous development into potential clinical grade applications.

Original language	English
Title of host publication	Progress in Molecular Biology and Translational Science
Editors	Akon Higuchi, Yinghong Zhou, Shih-Hwa Chiou
Publisher	Elsevier B.V.
Pages	131-154
Number of pages	24
ISBN (Print)	9780443134111
DOIs	https://doi.org/10.1016/bs.pmbts.2023.04.002
State	Published - Jan 2023

Publication series

Name	Progress in Molecular Biology and Translational Science
Volume	199
ISSN (Print)	1877-1173
ISSN (Electronic)	1878-0814

Access to Document

10.1016/bs.pmbts.2023.04.002

Cite this

Chiou, S. H., Ong, H. K. A., Chou, S. J., Aldoghachi, A. F., Loh, J. K., Verusingam, N. D., Yang, Y. P., & Chien, Y. (2023). Current trends and promising clinical utility of IPSC-derived MSC (iMSC). In A. Higuchi, Y. Zhou, & S.-H. Chiou (Eds.), Progress in Molecular Biology and Translational Science (pp. 131-154). (Progress in Molecular Biology and Translational Science; Vol. 199). Elsevier B.V.. https://doi.org/10.1016/bs.pmbts.2023.04.002

@inbook{dce608b0d2f440918d0a830b1bc36e77,

title = "Current trends and promising clinical utility of IPSC-derived MSC (iMSC)",

abstract = "Mesenchymal stem cells (MSCs) differentiated from human induced pluripotent stem cells (iPSC) or induced MSC (iMSCs) are expected to address issues of scalability and safety as well as the difficulty in producing homogenous clinical grade MSCs as demonstrated by the promising outcomes from preclinical and clinical trials, currently ongoing. The assessment of iMSCs based in vitro and in vivo studies have thus far showed more superior performance as compared to that of the primary or native human MSCs, in terms of cell proliferation, expansion capacity, immunomodulation properties as well as the influence of paracrine signaling and exosomal influence in cell-cell interaction. In this chapter, an overview of current well-established methods in generating a sustainable source of iMSCs involving well defined culture media is discussed followed by the properties of iMSC as compared to that of MSC and its promising prospects for continuous development into potential clinical grade applications.",

author = "Chiou, {Shih Hwa} and Ong, {Han Kiat Alan} and Chou, {Shih Jie} and Aldoghachi, {A. F.} and Loh, {Jit Kai} and Verusingam, {Nalini Devi} and Yang, {Yi Ping} and Yueh Chien",

note = "Publisher Copyright: {\textcopyright} 2023",

year = "2023",

month = jan,

doi = "10.1016/bs.pmbts.2023.04.002",

language = "English",

isbn = "9780443134111",

series = "Progress in Molecular Biology and Translational Science",

publisher = "Elsevier B.V.",

pages = "131--154",

editor = "Akon Higuchi and Yinghong Zhou and Shih-Hwa Chiou",

booktitle = "Progress in Molecular Biology and Translational Science",

address = "荷蘭",

}

Chiou, SH, Ong, HKA, Chou, SJ, Aldoghachi, AF, Loh, JK, Verusingam, ND, Yang, YP & Chien, Y 2023, Current trends and promising clinical utility of IPSC-derived MSC (iMSC). in A Higuchi, Y Zhou & S-H Chiou (eds), Progress in Molecular Biology and Translational Science. Progress in Molecular Biology and Translational Science, vol. 199, Elsevier B.V., pp. 131-154. https://doi.org/10.1016/bs.pmbts.2023.04.002

Current trends and promising clinical utility of IPSC-derived MSC (iMSC). / Chiou, Shih Hwa; Ong, Han Kiat Alan; Chou, Shih Jie et al.
Progress in Molecular Biology and Translational Science. ed. / Akon Higuchi; Yinghong Zhou; Shih-Hwa Chiou. Elsevier B.V., 2023. p. 131-154 (Progress in Molecular Biology and Translational Science; Vol. 199).

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

TY - CHAP

T1 - Current trends and promising clinical utility of IPSC-derived MSC (iMSC)

AU - Chiou, Shih Hwa

AU - Ong, Han Kiat Alan

AU - Chou, Shih Jie

AU - Aldoghachi, A. F.

AU - Loh, Jit Kai

AU - Verusingam, Nalini Devi

AU - Yang, Yi Ping

AU - Chien, Yueh

PY - 2023/1

Y1 - 2023/1

N2 - Mesenchymal stem cells (MSCs) differentiated from human induced pluripotent stem cells (iPSC) or induced MSC (iMSCs) are expected to address issues of scalability and safety as well as the difficulty in producing homogenous clinical grade MSCs as demonstrated by the promising outcomes from preclinical and clinical trials, currently ongoing. The assessment of iMSCs based in vitro and in vivo studies have thus far showed more superior performance as compared to that of the primary or native human MSCs, in terms of cell proliferation, expansion capacity, immunomodulation properties as well as the influence of paracrine signaling and exosomal influence in cell-cell interaction. In this chapter, an overview of current well-established methods in generating a sustainable source of iMSCs involving well defined culture media is discussed followed by the properties of iMSC as compared to that of MSC and its promising prospects for continuous development into potential clinical grade applications.

AB - Mesenchymal stem cells (MSCs) differentiated from human induced pluripotent stem cells (iPSC) or induced MSC (iMSCs) are expected to address issues of scalability and safety as well as the difficulty in producing homogenous clinical grade MSCs as demonstrated by the promising outcomes from preclinical and clinical trials, currently ongoing. The assessment of iMSCs based in vitro and in vivo studies have thus far showed more superior performance as compared to that of the primary or native human MSCs, in terms of cell proliferation, expansion capacity, immunomodulation properties as well as the influence of paracrine signaling and exosomal influence in cell-cell interaction. In this chapter, an overview of current well-established methods in generating a sustainable source of iMSCs involving well defined culture media is discussed followed by the properties of iMSC as compared to that of MSC and its promising prospects for continuous development into potential clinical grade applications.

UR - http://www.scopus.com/inward/record.url?scp=85166273789&partnerID=8YFLogxK

U2 - 10.1016/bs.pmbts.2023.04.002

DO - 10.1016/bs.pmbts.2023.04.002

M3 - Chapter

C2 - 37678969

AN - SCOPUS:85166273789

SN - 9780443134111

T3 - Progress in Molecular Biology and Translational Science

SP - 131

EP - 154

BT - Progress in Molecular Biology and Translational Science

A2 - Higuchi, Akon

A2 - Zhou, Yinghong

A2 - Chiou, Shih-Hwa

PB - Elsevier B.V.

ER -

Current trends and promising clinical utility of IPSC-derived MSC (iMSC)

Abstract

Publication series

Access to Document

Other files and links

Fingerprint

Cite this